CC INVESTOR ALERT

Bronstein, Gewirtz & Grossman LLC Announces that The Chemours Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Seite 3

The Complaint alleges that throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that:

(1) certain of the Company’s senior executive officers manipulated Free Cash Flow targets as a means to maximize additional cash and stock incentive compensation applicable to executive officers pursuant to the Company’s AIPs and LTIPs;

(2) the Company’s accounting practices and procedures, including its internal control over financial reporting, were deficient; and

(3) as a result, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

What’s Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CC or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Chemours you have until May 20, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240329358015/en/

The The Chemours Stock at the time of publication of the news with a fall of -8,65 % to 24,30USD on Tradegate stock exchange (28. März 2024, 22:26 Uhr).